Literature DB >> 28671211

Glucose directs amyloid-beta into membrane-active oligomers.

Niraja Kedia1, Michael Almisry1, Jan Bieschke1.   

Abstract

Oligomeric amyloid-β 1-42 (Aβ-42) peptides are considered to be the most toxic species connected to the occurrence of Alzheimer's disease. However, not all aggregation conditions promote oligomer formation in vitro, raising the question whether oligomer formation in vivo also requires a specific suitable cellular environment. We recently found that interaction with neuronal membranes initiates aggregation of Aβ-42 and neuronal uptake. Our data suggest that small molecules in the extracellular space can facilitate the formation of membrane-active Aβ-42 oligomers. We analyzed the early stage of Aβ-42 aggregation in the presence of glucose and sucrose and found that these sugars strongly favor Aβ-42 oligomer formation. We characterized oligomers by dynamic light scattering, atomic force microscopy, immuno-transmission electron microscopy and fluorescence cross correlation spectroscopy. We found that Aβ-42 spontaneously and rapidly forms low molecular weight oligomers in the presence of sugars. Slightly acidic pH (6.7-7) greatly favors oligomer formation when compared to the extracellular physiological pH (7.4). Circular dichroism demonstrated that these Aβ-42 oligomers did not adopt a β-sheet structure. Unstructured oligomeric Aβ-42 interacted with membrane bilayers of giant unilamellar vesicles (GUV) and neuronal model cells, facilitated cellular uptake of Aβ-42, and inhibition of mitochondrial activity. Our data therefore suggest that elevated concentrations of glucose within the range observed in diabetic individuals (10 mM) facilitate the formation of membrane-active Aβ-42 oligomers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671211      PMCID: PMC5654640          DOI: 10.1039/c7cp02849k

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  69 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid.

Authors:  Cyril C Curtain; Fedá E Ali; Danielle G Smith; Ashley I Bush; Colin L Masters; Kevin J Barnham
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

Review 3.  A dynamic view of cellular processes by in vivo fluorescence auto- and cross-correlation spectroscopy.

Authors:  Kirsten Bacia; Petra Schwille
Journal:  Methods       Date:  2003-01       Impact factor: 3.608

Review 4.  Signal transduction and endocytosis: close encounters of many kinds.

Authors:  Alexander Sorkin; Mark Von Zastrow
Journal:  Nat Rev Mol Cell Biol       Date:  2002-08       Impact factor: 94.444

Review 5.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

6.  Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity.

Authors:  J McLaurin; A Chakrabartty
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

7.  Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ.

Authors:  Kanchan Garai; Carl Frieden
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Lipid-induced beta-amyloid peptide assemblage fragmentation.

Authors:  Martin J O Widenbrant; Jayakumar Rajadas; Christopher Sutardja; Gerald G Fuller
Journal:  Biophys J       Date:  2006-12-01       Impact factor: 4.033

Review 9.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

Authors:  Velandai Srikanth; Annette Maczurek; Thanh Phan; Megan Steele; Bernadette Westcott; Damian Juskiw; Gerald Münch
Journal:  Neurobiol Aging       Date:  2009-05-22       Impact factor: 4.673

10.  Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer's disease.

Authors:  Wei Li; Tao Wang; Shifu Xiao
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-29       Impact factor: 2.570

View more
  7 in total

1.  Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation.

Authors:  Rachel L French; Zachary R Grese; Himani Aligireddy; Dhruva D Dhavale; Ashley N Reeb; Niraja Kedia; Paul T Kotzbauer; Jan Bieschke; Yuna M Ayala
Journal:  J Biol Chem       Date:  2019-03-01       Impact factor: 5.157

Review 2.  Amyloid β structural polymorphism, associated toxicity and therapeutic strategies.

Authors:  Ofek Oren; Ran Taube; Niv Papo
Journal:  Cell Mol Life Sci       Date:  2021-10-13       Impact factor: 9.261

3.  Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.

Authors:  Jeffrey Cummings; Andrew Ortiz; Janelle Castellino; Jefferson Kinney
Journal:  Eur J Neurosci       Date:  2022-02-06       Impact factor: 3.698

4.  hIAPP forms toxic oligomers in plasma.

Authors:  Diana C Rodriguez Camargo; Divita Garg; Katalin Buday; Andras Franko; Andres Rodriguez Camargo; Fabian Schmidt; Sarah J Cox; Saba Suladze; Martin Haslbeck; Yonatan G Mideksa; Gerd Gemmecker; Michaela Aichler; Gabriele Mettenleiter; Michael Schulz; Axel Karl Walch; Martin Hrabě de Angelis; Matthias J Feige; Cesar A Sierra; Marcus Conrad; Konstantinos Tripsianes; Ayyalusamy Ramamoorthy; Bernd Reif
Journal:  Chem Commun (Camb)       Date:  2018-05-24       Impact factor: 6.222

Review 5.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

Authors:  Erika N Cline; Maíra Assunção Bicca; Kirsten L Viola; William L Klein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Relationship of fasting glucose and longitudinal Alzheimer's disease imaging markers.

Authors:  Robyn A Honea; Casey S John; Zachary D Green; Paul J Kueck; Matthew K Taylor; Rebecca J Lepping; Ryan Townley; Eric D Vidoni; Jeffery M Burns; Jill K Morris
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01

7.  Impact of ConcanavalinA affinity in the intracellular fate of Protein Corona on Glucosamine Au nanoparticles.

Authors:  Desirè Di Silvio; Alessandro Silvestri; Luigi Lay; Laura Polito; Sergio E Moya
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.